Popular drugs for bone health linked to significantly lower Alzheimer's risk

Key Points:

• A large study of 121,492 adults aged 60 or older found that use of nitrogen-containing bisphosphonates (NBPs), common osteoporosis drugs, was linked to a 16% lower risk of developing Alzheimer's disease and related dementias compared to non-users, and a 24% lower risk compared to users of other osteoporosis medications.
• NBPs, such as alendronate and risedronate, are used to slow bone loss and reduce fracture risk in osteoporosis, a condition prevalent among older adults characterized by weakened bones.
• The study, conducted in Hong Kong and published in Alzheimer’s & Dementia, was observational and involved patients recently diagnosed with osteoporosis or serious fractures, with none having prior osteoporosis medication use.
• Researchers caution that the findings do not prove causation and highlight limitations including lack of baseline cognitive testing, absence of data on osteoporosis severity, and potential confounding factors like education and social isolation; thus, clinical trials are needed to confirm the protective effect.
• The authors emphasize the importance of maintaining bone health for potential dementia risk reduction and call for further research across diverse populations and examination of gender differences before recommending bisphosphonates for dementia prevention.